Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.
Sanofi is launching immunology drug Dupixent in several indications and the drug holds strong pricing power and major blockbuster potential across several indications.
Sanofi's deep entrenchment in China could come under duress, as Chinese officials are aggressively reviewing drug-marketing and pricing practices.
|
Metric
|
SAN
|
PFE
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 12.16 | 20.99 | 17.22 |
Price/Book Value | 1.89 | 1.85 | 6.52 |
Price/Sales | 2.71 | 2.91 | 4.57 |
Price/Cash Flow | 13.99 | 21.20 | 15.23 |
|
Metric
|
SAN
|
PFE
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.52 | 0.51 | 0.88 |
Current Ratio | 1.00 | 0.86 | 1.47 |
Interest Coverage | 8.61 | −0.88 | 13.07 |
|
Metric
|
SAN
|
PFE
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 7.59% | 3.50% | 15.46% |
Return on Equity (Normalized) | 14.17% | 8.28% | 41.15% |
Return on Invested Capital (Normalized) | 10.36% | 5.39% | 22.92% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Nzcxncqkr | Jtyly | $802.3 Bil | |||
| Johnson & Johnson
JNJ
| Xgzqbhhdw | Njys | $388.0 Bil | |||
| AbbVie Inc
ABBV
| Xmblncsr | Ckpt | $347.7 Bil | |||
| Merck & Co Inc
MRK
| Tbtvwzzt | Wsjrh | $284.1 Bil | |||
| Roche Holding AG ADR
RHHBY
| Xfctjnth | Pgvs | $252.2 Bil | |||
| AstraZeneca PLC ADR
AZN
| Kmvhdgkvz | Nszg | $245.8 Bil | |||
| Novartis AG ADR
NVS
| Rwgfflfr | Qkkk | $232.6 Bil | |||
| Amgen Inc
AMGN
| Vzmcrvjzz | Mqr | $171.8 Bil | |||
| Pfizer Inc
PFE
| Tdqfnzh | Nlv | $162.1 Bil | |||
| Sanofi SA ADR
SNY
| Clrcdwvs | Yxjd | $141.7 Bil |
:quality(80)/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)
United States